Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000346313> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W3000346313 abstract "ABSTRACT Introduction Pemetrexed (Pem) has been approved for the treatment of advanced non small cell lung cancer (NSCLC) non-squamous histology, both as 1° and 2° line therapy with or without platinum compounds, respectively. Pem is an antimetabolite drug, that inhibits enzymes involved in nucleotides bio-synthesis arresting cancer cells cycle. Literature data show the effect of antimetabolities on increment of erythrocyte mean corpuscolar volume (MCV) in cancer patients (pts) treated with capecitabine and, recently, a positive correlation between increased MCV and response to capecitabine-based therapy has emerged [Arslan et al, Tumori 2011; Dellapasqua et al, Breast 2012]. The aim of this study was the evaluation of the impact of Pem on MCV change and its possible correlation with disease control rate (overall response + stable disease rate) (DCR), progression free survival (PFS) and overall survival (OS) in NSCLC pts. Methods A retrospective collection of clinical and laboratory data (including basal MCV and maximum MCV occurred during Pem therapy) in 165 advanced NSCLC pts treated with Pem from 4 Italian centres was performed. Results Pts characteristics: 59% men, median age 64 years (range 36-83), 58% ECOG PS 0, 90% stage IV and 10% stage IIIB (according 6th TNM), 87% adenocarcinoma histotype, 74% current or ex-smokers, 59% as 1° line, 41% as ≥ 2° line, 68% in combination with a platinum compound, median cycle 4 (range 1-29). All pts received vitamin B12 and folic acid supplementation. Mean MCV significantly increased from basal (89.6 fl) to “during treatment” (94.8 fl), with mean ΔMCV = 5.2 fl (t test for paired data, p 5 fl (n = 68) and in ΔMCV ≤ 5 fl (n = 97) pts, respectively. Conclusion Pem induces significant increase of erythrocyte MCV. ΔMCV > 5 fl on Pem therapy appears to be correlated with better DCR, PFS and OS. These data should be related to a decreased metabolism of Pem and subsequent increased drug exposure in pts who develop higher ΔMCV during treatment. A larger prospective evaluation could be useful to better clarify these findings. Disclosure All authors have declared no conflicts of interest." @default.
- W3000346313 created "2020-01-23" @default.
- W3000346313 creator A5001428569 @default.
- W3000346313 creator A5002069319 @default.
- W3000346313 creator A5013913173 @default.
- W3000346313 creator A5016711314 @default.
- W3000346313 creator A5016783216 @default.
- W3000346313 creator A5018508203 @default.
- W3000346313 creator A5030465858 @default.
- W3000346313 creator A5032386417 @default.
- W3000346313 creator A5071783009 @default.
- W3000346313 creator A5084034066 @default.
- W3000346313 date "2012-09-01" @default.
- W3000346313 modified "2023-09-26" @default.
- W3000346313 title "Erythrocyte Mean Corpuscular Volume Change During Pemetrexed Treatment in Advanced Non Small Cell Lung Cancer Patients" @default.
- W3000346313 doi "https://doi.org/10.1016/s0923-7534(20)33818-7" @default.
- W3000346313 hasPublicationYear "2012" @default.
- W3000346313 type Work @default.
- W3000346313 sameAs 3000346313 @default.
- W3000346313 citedByCount "0" @default.
- W3000346313 crossrefType "journal-article" @default.
- W3000346313 hasAuthorship W3000346313A5001428569 @default.
- W3000346313 hasAuthorship W3000346313A5002069319 @default.
- W3000346313 hasAuthorship W3000346313A5013913173 @default.
- W3000346313 hasAuthorship W3000346313A5016711314 @default.
- W3000346313 hasAuthorship W3000346313A5016783216 @default.
- W3000346313 hasAuthorship W3000346313A5018508203 @default.
- W3000346313 hasAuthorship W3000346313A5030465858 @default.
- W3000346313 hasAuthorship W3000346313A5032386417 @default.
- W3000346313 hasAuthorship W3000346313A5071783009 @default.
- W3000346313 hasAuthorship W3000346313A5084034066 @default.
- W3000346313 hasBestOaLocation W30003463131 @default.
- W3000346313 hasConcept C121608353 @default.
- W3000346313 hasConcept C126322002 @default.
- W3000346313 hasConcept C143998085 @default.
- W3000346313 hasConcept C2776256026 @default.
- W3000346313 hasConcept C2776694085 @default.
- W3000346313 hasConcept C2777240266 @default.
- W3000346313 hasConcept C2777909004 @default.
- W3000346313 hasConcept C2778239845 @default.
- W3000346313 hasConcept C2778397455 @default.
- W3000346313 hasConcept C2778917026 @default.
- W3000346313 hasConcept C2780258809 @default.
- W3000346313 hasConcept C2780350996 @default.
- W3000346313 hasConcept C2781058662 @default.
- W3000346313 hasConcept C526805850 @default.
- W3000346313 hasConcept C71924100 @default.
- W3000346313 hasConcept C90924648 @default.
- W3000346313 hasConceptScore W3000346313C121608353 @default.
- W3000346313 hasConceptScore W3000346313C126322002 @default.
- W3000346313 hasConceptScore W3000346313C143998085 @default.
- W3000346313 hasConceptScore W3000346313C2776256026 @default.
- W3000346313 hasConceptScore W3000346313C2776694085 @default.
- W3000346313 hasConceptScore W3000346313C2777240266 @default.
- W3000346313 hasConceptScore W3000346313C2777909004 @default.
- W3000346313 hasConceptScore W3000346313C2778239845 @default.
- W3000346313 hasConceptScore W3000346313C2778397455 @default.
- W3000346313 hasConceptScore W3000346313C2778917026 @default.
- W3000346313 hasConceptScore W3000346313C2780258809 @default.
- W3000346313 hasConceptScore W3000346313C2780350996 @default.
- W3000346313 hasConceptScore W3000346313C2781058662 @default.
- W3000346313 hasConceptScore W3000346313C526805850 @default.
- W3000346313 hasConceptScore W3000346313C71924100 @default.
- W3000346313 hasConceptScore W3000346313C90924648 @default.
- W3000346313 hasLocation W30003463131 @default.
- W3000346313 hasOpenAccess W3000346313 @default.
- W3000346313 hasPrimaryLocation W30003463131 @default.
- W3000346313 hasRelatedWork W2014478553 @default.
- W3000346313 hasRelatedWork W2015607696 @default.
- W3000346313 hasRelatedWork W2077066334 @default.
- W3000346313 hasRelatedWork W2080773827 @default.
- W3000346313 hasRelatedWork W2080821717 @default.
- W3000346313 hasRelatedWork W2145939327 @default.
- W3000346313 hasRelatedWork W2314610986 @default.
- W3000346313 hasRelatedWork W2337216642 @default.
- W3000346313 hasRelatedWork W2347248699 @default.
- W3000346313 hasRelatedWork W2353591255 @default.
- W3000346313 hasRelatedWork W2359987967 @default.
- W3000346313 hasRelatedWork W2369560177 @default.
- W3000346313 hasRelatedWork W2729328523 @default.
- W3000346313 hasRelatedWork W2779590255 @default.
- W3000346313 hasRelatedWork W2791311833 @default.
- W3000346313 hasRelatedWork W2791848898 @default.
- W3000346313 hasRelatedWork W3027663706 @default.
- W3000346313 hasRelatedWork W3032225046 @default.
- W3000346313 hasRelatedWork W3092885209 @default.
- W3000346313 hasRelatedWork W3160876096 @default.
- W3000346313 isParatext "false" @default.
- W3000346313 isRetracted "false" @default.
- W3000346313 magId "3000346313" @default.
- W3000346313 workType "article" @default.